Ozone Therapy for Fibromyalgia: ISCO3 Complementary-Treatment Guideline

Background

Fibromyalgia is a long-term condition marked by widespread musculoskeletal pain, usually alongside persistent fatigue, disturbed sleep and difficulty with concentration and memory (sometimes described as "fibro fog"). It is thought to affect roughly 2-3% of the population and is more common in women. Unlike arthritis or a physical injury, fibromyalgia produces no clear structural damage that shows up on scans or blood tests, which makes it difficult both to diagnose and to treat. Conventional management usually combines medication, exercise and psychological support, but many people continue to have symptoms, and interest in complementary approaches such as ozone therapy has grown as a result.

What this document is

This is a Standard Operating Procedure issued by the International Scientific Committee of Ozone Therapy (ISCO3), a body that publishes consensus guidance on how ozone therapy should be delivered. It is not a single clinical trial and does not report original patient data. Instead it sets out the committee's recommended approach to using ozone as a complementary treatment for fibromyalgia, drawing on the authors' clinical experience and on the wider ozone-therapy literature. The document reviews the biological factors that may contribute to fibromyalgia - including immune dysfunction, oxidative stress, imbalances in the gut microbiome and neuroendocrine disruption - and then describes how ozone might be applied in practice.

What it reports

The guideline describes four routes of administration for fibromyalgia: ozonated saline solution, major autohaemotherapy (in which a small volume of the patient's blood is mixed with an ozone-oxygen mixture and returned to the body), rectal insufflation, and minor autohaemotherapy. It also notes the use of local injections at tender points. For each route it sets out suggested concentrations, volumes and treatment schedules. The committee grades the supporting evidence as "Level C", reflecting small clinical trials rather than large randomised studies, and reports that these trials have described symptomatic improvement - in pain, fatigue and quality of life - in a majority of the patients treated.

What the authors concluded

The authors conclude that the available clinical trials give some support for using ozone as a complementary therapy in fibromyalgia, and that it may help to reduce pain and fatigue and improve quality of life for some patients. They are careful to frame ozone as an adjunct to conventional care rather than a replacement for it. They also state plainly that larger and more rigorous studies are needed before firm conclusions can be drawn about how effective the treatment is and how long any benefit might last.

Limitations of this document

This is an expert-committee guideline, not a controlled clinical trial. It reflects the consensus and clinical experience of its authors and of the ISCO3, and it has not been published in a peer-reviewed journal or assigned a DOI. The evidence it draws on is graded "Level C" and comes largely from small, uncontrolled studies, a limitation the document itself acknowledges. Sources of this kind can describe how a treatment is used and what practitioners observe, but they cannot establish that ozone therapy is effective for fibromyalgia - only large, well-designed randomised controlled trials can do that. The protocols it sets out should be read as guidance for qualified practitioners and discussed with a healthcare professional, not as proof of benefit.